Efficiency of Levilimab in patients with moderate and severe COVID-19

Abstract

Objective: evaluation of the clinical and economic efficiency of using Levilimab in the treatment of moderate and severe COVID-19 based on real world data (RWD).Material and methods. A single-center observational retrospective case-control study was performed. According to the matching algorithm, 834 pairs of patients with moderate and 347 pairs with severe infection were selected, similar in gender, age, vaccination status, severity of the disease and the level of C-reactive protein.Results. The clinical efficiency of Levilimab with respect to in-hospital mortality was demonstrated both for the moderate course (6% in the Levilimab group and 10% in the standard therapy group; odds ratio (OR) 1.71; 95% confidence interval (CI) 1.19–2.47; p<0.01) and for the severe course of COVID-19 (63% and 82%, respectively; OR 2.70; 95% CI 1.90–3.82; p<0.01). The costs per 1 treated patient were also higher in the Levilimab therapy groups: the difference in costs compared to the standard therapy group for patients with moderate disease was 54 665.30 rubles, with severe disease – 91 285.85 rubles. The estimated cost of the additional effectiveness of Levilimab for the moderate course of the disease was 13,666.32 rubles, for the severe course – 4,804.51 rubles.Conclusion. The use of Levilimab for the treatment of moderate and severe COVID-19 is feasible both from a clinical and economic points of view. Conducting RWD trials is an important tool to understand the effectiveness of medical technologies in real clinical practice.

Keywords

• levilimab
• anti-interleukin therapy
• novel coronavirus infection
• covid-19
• economic efficiency